Analyst taking note!
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) Shares Building Momentum
By Michael Luke - April 6, 2017
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) shares more than doubled in a one month period recently. Now, if you’ve been following us, we talked about some catalysts in IMLFF that might have caused the stock to rise. There’s one major development that’s coming up soon, and it could be good news for companies.
If you haven’t heard about InMed Pharmaceuticals yet, it’s a pre-clinical biopharma company specializing in the development of therapies through research and development (R&D) into the extensive pharmacology of cannabinoids intertwined with innovative drug delivery systems. In the company’s own words, “InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.”
That said, INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) could be ripe for growth. If you haven’t been following the news, Canada has a legalization bill in the works for the legalization of cannabis, both for recreational and medicinal use, throughout the whole country. That in mind, this is a positive catalyst for the InMed Pharma, since it is based in Canada. Therefore, brands that already have an established presence in Canada, could benefit significantly from the potential legalization of marijuana.
If you haven’t been keeping up with InMed Pharmaceutical, it’s also had some positive company news. The company was featured in a Forbes article, “InMed Pharmaceuticals Is More Than Just Another Cannabis Drug Company“, which discussed the its innovative database, mapping out an array of cannabinoid combinations and a variety of diseases that they could possibly address.
The company is currently developing two drug candidates through preclinical testing and it’s targeting clinical programs for EB, a rare genetic skin disorder, and glaucoma. InMed’s management plans to begin EB clinical trials in 2018, and thereafter it is looking to begin trials with glaucoma and pain therapies. The company believes that the market for EB will exceed $1B per year. Additionally, the current market for glaucoma drugs is over $6B per year. That said, if InMed Properly executes, it could significantly drive the company’s revenues and earnings higher. In turn, this could potentially push the stock higher.
CFN Media Group, one of the leading creative agencies and digital media networks focused on legal cannabis, recently covered InMed Pharma and stated, “InMed Pharma has taken a more precise approach to the drug discovery process than most competitors via its bioinformatics platform. Using extensive databases and proprietary algorithms, the technology rapidly identifies cannabinoid combinations that are likely to have an effect on specific diseases. This helps them dramatically shorten the drug discovery period and increases the likelihood of success from the onset of drug development.
Once they’ve isolated promising cannabinoid compounds, the company isolates the genes responsible for producing them and injects the genes with bacteria that act as a factory for mass producing them in a process similar to the way insulin is manufactured. The company can then combine these various compounds to create unique therapies that target specific diseases without having to worry about costly extraction from entire cannabis plants.”
That in mind, InMed Pharmaceuticals is gaining some media coverage, which could increase brand awareness, and potentially drive more patients to the company, if and when it gains approval for its drug candidates. You might want to stay on top of company, as well as industry news because the stock could start moving again, with the cannabis legalization bill coming up soon. To stay on top of developments in IMLFF, you don’t have to be on your computer or tablet all day. You could subscribe to our free newsletter by simply entering your email address below, and only then we would email you on updates, if any, in the IMLFF.
